Clinical trials in Chaidari – page 38

1 008 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GreeceΚλινικεσΔοκιμεσ.gr

Chaidari at a glance

1 008

clinical trials

Research sites1

Quick filters

1 008 trials in Chaidari

Open in trial search

Type 2 diabetes mellitus

Not recruiting

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Dulaglutide
Sponsor:Eli Lilly & Co.

Contact Research Centre

Obesity+1

Not recruiting

Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

Registered drug

Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Olpasiran
Sponsor:Amgen Inc.

Contact Research Centre

Colitis ulcerative+1

Not recruiting

A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis

Investigational

A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Balinatunfib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Dazodalibep
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Dazodalibep
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Dazodalibep
Sponsor:Amgen Inc.

Contact Research Centre

Type 2 diabetes mellitus+3

Not recruiting

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Sjogren's syndrome

Not recruiting

A Study Testing Imeroprubart for Adults with Primary Sjogren's Disease with Moderate to Severe Symptoms

Investigational

A Study Testing Imeroprubart for Adults with Primary Sjogren's Disease with Moderate to Severe Symptoms

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Imeroprubart
Sponsor:Immunovant Sciences GmbH

Contact Research Centre

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries